INVA
INVA
NASDAQ · Pharmaceuticals

Innoviva Inc

$21.12
+0.08 (+0.38%)
As of Sep 22, 1:45 PM ET ·
Financial Highlights (FY 2026)
Revenue
345.95M
Net Income
228.06M
Gross Margin
74.8%
Profit Margin
65.9%
Rev Growth
+7.5%
D/E Ratio
0.22
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 74.8% 74.8% 67.3% 67.3%
Operating Margin 39.8% 35.8% 36.7% 43.7%
Profit Margin 65.9% 62.6% 33.9% 33.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 345.95M 321.88M 296.49M 325.02M
Gross Profit 258.77M 240.76M 199.68M 218.90M
Operating Income 137.72M 115.32M 108.77M 141.90M
Net Income 228.06M 190.97M 100.45M 107.69M
Gross Margin 74.8% 74.8% 67.3% 67.3%
Operating Margin 39.8% 35.8% 36.7% 43.7%
Profit Margin 65.9% 62.6% 33.9% 33.1%
Rev Growth +7.5% +7.5% +12.4% +2.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 135.60M 135.60M 569.66M 644.56M
Total Equity 617.20M 617.20M 1.17B 1.19B
D/E Ratio 0.22 0.22 0.49 0.54
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 149.45M 132.10M 161.71M 177.91M
Free Cash Flow 84.32M 106.96M